Literature DB >> 23881705

Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis.

Weihua Zhao1, David R Beers, Stanley H Appel.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with selective loss of upper and lower motor neurons. At sites of motor neuron injury, neuroinflammation is a prominent pathological finding and is characterized by microglial activation, astrogliosis, and infiltration of monocytes and T-cells. Both innate and adaptive immune responses actively influence disease progression in animal models and in ALS patients, and promote neuroprotection or neurotoxicity at different stages of disease. The early immune reaction to signals from injured motor neurons is to rescue and repair damaged tissue. As disease accelerates, a shift occurs from beneficial immune responses (involving M2 microglia and regulatory T-cells) to deleterious immune responses (involving M1 microglia and Th1 cells). In this review, we underscore the importance of immune-mediated mechanisms in the pathogenesis of ALS and discuss the alterations and distinct phenotypes of immune cells at the different stages of disease. The better we understand the dynamic changes that occur within the immune system over the course of disease, the better we will be able to develop effective therapeutic regimens in ALS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881705      PMCID: PMC4126425          DOI: 10.1007/s11481-013-9489-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  79 in total

1.  Alterations of T cell subsets in ALS: a systemic immune activation?

Authors:  M Rentzos; E Evangelopoulos; E Sereti; V Zouvelou; S Marmara; T Alexakis; I Evdokimidis
Journal:  Acta Neurol Scand       Date:  2011-06-09       Impact factor: 3.209

2.  Non-viral gene delivery of the GDNF, either alone or fused to the C-fragment of tetanus toxin protein, prolongs survival in a mouse ALS model.

Authors:  María Moreno-Igoa; Ana Cristina Calvo; Jesús Ciriza; María Jesús Muñoz; Pilar Zaragoza; Rosario Osta
Journal:  Restor Neurol Neurosci       Date:  2012       Impact factor: 2.406

3.  An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.

Authors:  Stefania Guareschi; Emanuela Cova; Cristina Cereda; Mauro Ceroni; Elena Donetti; Daryl A Bosco; Davide Trotti; Piera Pasinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-13       Impact factor: 11.205

4.  Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment.

Authors:  A Pramatarova; J Laganière; J Roussel; K Brisebois; G A Rouleau
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

5.  Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.

Authors:  Li-Jun Wang; Yan-Yan Lu; Shin-ichi Muramatsu; Kunihiko Ikeguchi; Ken-ichi Fujimoto; Takashi Okada; Hiroaki Mizukami; Takashi Matsushita; Yutaka Hanazono; Akihiro Kume; Toshiharu Nagatsu; Keiya Ozawa; Imaharu Nakano
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

6.  Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice.

Authors:  Isaac M Chiu; Hemali Phatnani; Michael Kuligowski; Juan C Tapia; Monica A Carrasco; Ming Zhang; Tom Maniatis; Michael C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-20       Impact factor: 11.205

7.  Increased cytotoxic potential of microglia from ALS-transgenic mice.

Authors:  Patrick Weydt; Eric C Yuen; Bruce R Ransom; Thomas Möller
Journal:  Glia       Date:  2004-11-01       Impact factor: 7.452

8.  Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia.

Authors:  Qin Xiao; Weihua Zhao; David R Beers; Albert A Yen; Wenjie Xie; Jenny S Henkel; Stanley H Appel
Journal:  J Neurochem       Date:  2007-06-07       Impact factor: 5.372

9.  Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.

Authors:  Oleg Butovsky; Shafiuddin Siddiqui; Galina Gabriely; Amanda J Lanser; Ben Dake; Gopal Murugaiyan; Camille E Doykan; Pauline M Wu; Reddy R Gali; Lakshmanan K Iyer; Robert Lawson; James Berry; Anna M Krichevsky; Merit E Cudkowicz; Howard L Weiner
Journal:  J Clin Invest       Date:  2012-08-06       Impact factor: 14.808

10.  MyD88-deficient bone marrow cells accelerate onset and reduce survival in a mouse model of amyotrophic lateral sclerosis.

Authors:  Jihong Kang; Serge Rivest
Journal:  J Cell Biol       Date:  2007-12-17       Impact factor: 10.539

View more
  115 in total

Review 1.  Glial cells in amyotrophic lateral sclerosis.

Authors:  T Philips; J D Rothstein
Journal:  Exp Neurol       Date:  2014-05-22       Impact factor: 5.330

Review 2.  Microglial M1/M2 polarization and metabolic states.

Authors:  Ruben Orihuela; Christopher A McPherson; Gaylia Jean Harry
Journal:  Br J Pharmacol       Date:  2015-05-11       Impact factor: 8.739

Review 3.  Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.

Authors:  Kristopher G Hooten; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

4.  Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease.

Authors:  Aaron Burberry; Naoki Suzuki; Jin-Yuan Wang; Rob Moccia; Daniel A Mordes; Morag H Stewart; Satomi Suzuki-Uematsu; Sulagna Ghosh; Ajay Singh; Florian T Merkle; Kathryn Koszka; Quan-Zhen Li; Leonard Zon; Derrick J Rossi; Jennifer J Trowbridge; Luigi D Notarangelo; Kevin Eggan
Journal:  Sci Transl Med       Date:  2016-07-13       Impact factor: 17.956

5.  Adoptive transfer of IL-10+ regulatory B cells decreases myeloid-derived macrophages in the central nervous system in a transgenic amyotrophic lateral sclerosis model.

Authors:  Andrea Pennati; Seneshaw Asress; Jonathan D Glass; Jacques Galipeau
Journal:  Cell Mol Immunol       Date:  2018-01-08       Impact factor: 11.530

Review 6.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

7.  Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes.

Authors:  Weihua Zhao; David R Beers; Kristopher G Hooten; Douglas H Sieglaff; Aijun Zhang; Shanker Kalyana-Sundaram; Christopher M Traini; Wendy S Halsey; Ashley M Hughes; Ganesh M Sathe; George P Livi; Guo-Huang Fan; Stanley H Appel
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

8.  Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Savina Apolloni; Paola Fabbrizio; Chiara Parisi; Susanna Amadio; Cinzia Volonté
Journal:  Mol Neurobiol       Date:  2014-12-09       Impact factor: 5.590

9.  Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction.

Authors:  Audrey Yi Tyan Peng; Ira Agrawal; Wan Yun Ho; Yi-Chun Yen; Ashley J Pinter; Jerry Liu; Qi Xuan Cheryl Phua; Katrianne Bethia Koh; Jer-Cherng Chang; Emma Sanford; Jodie Hon Kiu Man; Peiyan Wong; David H Gutmann; Greg Tucker-Kellogg; Shuo-Chien Ling
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-30       Impact factor: 11.205

10.  Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Rosa Luisa Potenza; Roberta De Simone; Monica Armida; Valentina Mazziotti; Antonella Pèzzola; Patrizia Popoli; Luisa Minghetti
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.